CCL2 and neoplasm: Surprisingly anti-CCL2 monoclonal antibody treatment did not affect TAM recruitment but polarized TAMs to a more antitumor phenotype, where the tumor regression was CD8+ T-cell dependent in a murine NSCLC cancer model [123] (Table 1).